Market Cap | 9.77M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | 5.2M | Forward P/E | -0.34 | EPS next Y | - | 50D Avg Chg | -12.00% |
Sales | 3.2M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -70.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -84.00% |
Recommedations | 3.00 | Quick Ratio | 0.63 | Shares Outstanding | 3.41M | 52W Low Chg | 41.00% |
Insider Own | 1.73% | ROA | -59.37% | Shares Float | 3.35M | Beta | 1.35 |
Inst Own | 4.04% | ROE | - | Shares Shorted/Prior | 166.13K/124.05K | Price | 0.37 |
Gross Margin | -278.31% | Profit Margin | 162.34% | Avg. Volume | 315,669 | Target Price | 6.00 |
Oper. Margin | -5,294.55% | Earnings Date | Nov 7 | Volume | 3,392,375 | Change | 14.06% |
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
HC Wainwright & Co. | Neutral | Jul 1, 24 |
HC Wainwright & Co. | Buy | Apr 3, 24 |
HC Wainwright & Co. | Buy | Mar 6, 24 |
HC Wainwright & Co. | Buy | Nov 20, 23 |
JonesTrading | Hold | Aug 21, 23 |
Baird | Outperform | Aug 15, 23 |
Maxim Group | Buy | May 11, 23 |
Baird | Outperform | May 11, 23 |
HC Wainwright & Co. | Buy | Mar 9, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
THEUER CHARLES | President and CEO President and CEO | Apr 26 | Buy | 0.71 | 50,999 | 36,209 | 399,417 | 04/28/23 |
THEUER CHARLES | President and CEO President and CEO | Feb 28 | Buy | 1.52 | 5,000 | 7,600 | 344,918 | 03/02/23 |
THEUER CHARLES | President and CEO President and CEO | Jan 18 | Buy | 1.62 | 6,800 | 11,016 | 339,918 | 01/19/23 |
LARUE WILLIAM R | Director Director | Dec 21 | Sell | 1.2553 | 120 | 151 | 7,763 | 01/19/23 |
Brown Scott B. | Chief Financial Offi.. Chief Financial Officer | Dec 29 | Buy | 1.49 | 3,500 | 5,215 | 21,628 | 01/03/23 |
Opaleye Management Inc. | 10% Owner 10% Owner | Dec 14 | Buy | 1.25 | 167,500 | 209,375 | 440,000 | 12/16/22 |
THEUER CHARLES | President and CEO President and CEO | Dec 14 | Buy | 1.2937 | 23,000 | 29,755 | 333,118 | 12/15/22 |
Opaleye Management Inc. | 10% Owner 10% Owner | Dec 06 | Sell | 1.44 | 1,539 | 2,216 | 4,010,000 | 12/08/22 |
THEUER CHARLES | President and CEO President and CEO | Nov 18 | Buy | 1.41 | 13,900 | 19,599 | 310,118 | 11/22/22 |
THEUER CHARLES | President and CEO President and CEO | Nov 03 | Buy | 1.52 | 9,200 | 13,984 | 296,218 | 11/04/22 |
THEUER CHARLES | President and CEO President and CEO | Nov 02 | Buy | 1.59 | 6,000 | 9,540 | 287,018 | 11/03/22 |
Opaleye Management Inc. | 10% Owner 10% Owner | Oct 18 | Buy | 1.65 | 12,500 | 20,625 | 4,125,000 | 10/19/22 |
THEUER CHARLES | President and CEO President and CEO | Oct 03 | Buy | 1.67 | 5,000 | 8,350 | 272,518 | 10/05/22 |
Opaleye Management Inc. | 10% Owner 10% Owner | Sep 29 | Buy | 1.7415 | 9,400 | 16,370 | 410,000 | 10/03/22 |
Opaleye Management Inc. | 10% Owner 10% Owner | Sep 27 | Buy | 1.6924 | 1,700 | 2,877 | 400,600 | 09/28/22 |
THEUER CHARLES | President and CEO President and CEO | Sep 22 | Buy | 1.76 | 5,000 | 8,800 | 267,518 | 09/26/22 |
Opaleye Management Inc. | 10% Owner 10% Owner | Sep 22 | Buy | 1.73 | 17,311 | 29,948 | 398,900 | 09/22/22 |
Opaleye Management Inc. | 10% Owner 10% Owner | Sep 19 | Buy | 1.8733 | 5,000 | 9,366 | 375,000 | 09/19/22 |
Opaleye Management Inc. | 10% Owner 10% Owner | Jul 26 | Buy | 1.72 | 2,254 | 3,877 | 370,000 | 07/26/22 |
THEUER CHARLES | President and CEO President and CEO | Jul 22 | Buy | 1.85 | 4,500 | 8,325 | 262,518 | 07/25/22 |
Opaleye Management Inc. | 10% Owner 10% Owner | Jul 15 | Buy | 1.7815 | 11,826 | 21,068 | 367,746 | 07/15/22 |
Opaleye Management Inc. | 10% Owner 10% Owner | Jul 14 | Buy | 1.8122 | 7,187 | 13,024 | 355,920 | 07/14/22 |
THEUER CHARLES | President and CEO President and CEO | Jul 12 | Buy | 1.86 | 6,000 | 11,160 | 258,018 | 07/14/22 |
Opaleye Management Inc. | 10% Owner 10% Owner | Jun 24 | Buy | 1.3919 | 11,419 | 15,894 | 348,733 | 06/27/22 |
Opaleye Management Inc. | 10% Owner 10% Owner | Jun 21 | Buy | 1.3127 | 841,989 | 1,105,279 | 3,776,589 | 06/23/22 |
THEUER CHARLES | President and CEO President and CEO | May 09 | Buy | 1.85 | 10,000 | 18,500 | 252,018 | 05/11/22 |
Opaleye Management Inc. | 10% Owner 10% Owner | May 10 | Buy | 1.76 | 9,700 | 17,072 | 337,314 | 05/10/22 |
THEUER CHARLES | President and CEO President and CEO | May 06 | Buy | 1.97 | 2,500 | 4,925 | 242,018 | 05/10/22 |
THEUER CHARLES | President and CEO President and CEO | Apr 29 | Buy | 1.9709 | 5,000 | 9,854 | 239,518 | 05/03/22 |
Opaleye Management Inc. | 10% Owner 10% Owner | Apr 29 | Buy | 1.98 | 7,100 | 14,058 | 336,114 | 04/29/22 |
Opaleye Management Inc. | 10% Owner 10% Owner | Apr 22 | Buy | 2.21 | 52,777 | 116,637 | 335,114 | 04/25/22 |
THEUER CHARLES | President and CEO President and CEO | Apr 21 | Buy | 2.30 | 4,500 | 10,350 | 234,518 | 04/25/22 |
Opaleye Management Inc. | 10% Owner 10% Owner | Apr 13 | Buy | 2.5 | 20,041 | 50,102 | 330,041 | 04/14/22 |
Opaleye Management Inc. | 10% Owner 10% Owner | Apr 11 | Buy | 2.45 | 27,198 | 66,635 | 325,000 | 04/12/22 |
THEUER CHARLES | President and CEO President and CEO | Apr 08 | Buy | 2.50 | 2,000 | 5,000 | 226,518 | 04/12/22 |
THEUER CHARLES | President and CEO President and CEO | Mar 30 | Buy | 2.70 | 4,000 | 10,800 | 224,518 | 04/01/22 |
Brown Scott B. | Chief Financial Offi.. Chief Financial Officer | Mar 29 | Buy | 2.82 | 1,000 | 2,820 | 8,628 | 03/30/22 |
THEUER CHARLES | President and CEO President and CEO | Mar 21 | Buy | 2.45 | 1,200 | 2,940 | 220,518 | 03/23/22 |
Opaleye Management Inc. | 10% Owner 10% Owner | Mar 16 | Buy | 2.20 | 2,235 | 4,917 | 2,837,735 | 03/17/22 |
Opaleye Management Inc. | 10% Owner 10% Owner | Jan 21 | Buy | 2.12 | 52,363 | 111,010 | 317,363 | 01/24/22 |
Opaleye Management Inc. | 10% Owner 10% Owner | Dec 29 | Buy | 2.51 | 52,325 | 131,336 | 305,000 | 12/29/21 |
WIGGINS MARK C | Chief Business Offic.. Chief Business Officer | Dec 30 | Buy | 10.57 | 1,000 | 10,570 | 13,700 | 12/30/20 |
Opaleye Management Inc. | 10% Owner 10% Owner | Oct 23 | Buy | 4.4 | 8,656 | 38,086 | 1,797,094 | 10/23/20 |
Opaleye Management Inc. | 10% Owner 10% Owner | Sep 25 | Buy | 4.64 | 78,734 | 365,326 | 1,785,438 | 09/25/20 |